Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 5/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CDC25B | P30305 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31187611 | 1.00 | ALDH1A1 (0.47) | ALDH1A1NR4A1NR4A2NR4A3LMNA | |
| Hydrochloric Acid SCHEMBL11618161 | 0.98 | ALDH1A1 (0.46) | ALDH1A1NR4A1NR4A2NR4A3LMNA | |
| SCHEMBL528715 | 0.84 | PARP1 (0.62) | PARP1 | |
| SCHEMBL29558330 | 0.84 | PARP1 (0.62) | PARP1 | |
| Hydrochloric Acid SCHEMBL31382875 | 0.83 | PARP1 (0.60) | PARP1 | |
| SCHEMBL6390643 | 0.82 | TRPV1 (0.39) | ALDH1A1NR4A1NR4A2NR4A3LMNA | |
| SCHEMBL27949789 | 0.81 | PARP1 (0.40) | ALDH1A1PARP1TRPV1EGFRTDP1 | |
| SCHEMBL30013145 | 0.80 | PKN1 (0.46) | ALDH1A1LMNAHSD17B10PARP1TRPV1 | |
| SCHEMBL29829237 | 0.80 | PKN1 (0.46) | ALDH1A1HSD17B10PARP1TRPV1EGFR | |
| SCHEMBL666445 | 0.80 | PLK1 (0.50) | PARP1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4072670-B1 | QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | CHIESI FARM SPA (IT) | 2023-11-22 | — | — | EP | claimed |
| EP-3230273-A1 | 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG | Cancer Research Technology Ltd (GB) | 2017-10-18 | — | — | EP | claimed |
| WO-2016092326-A1 | 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-06-16 | — | — | WO | claimed |
| US-20130018033-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2013-01-17 | — | — | US | claimed |
| US-4083980-A | ANTIALLERGENS | BOEHRINGER INGELHEIM GMBH (DT) | 1978-04-11 | — | — | US | claimed |
| CN-119487031-A | Tryptanthrin derivatives and uses thereof | 威森特生物公司 | 2025-02-18 | — | — | CN | disclosed |
| EP-4392425-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND USE THEREOF | Impact Therapeutics (Shanghai), Inc. (CN) | 2024-07-03 | — | — | EP | disclosed |
| WO-2023126951-A1 | INHIBITORS OF AUTOPHAGY-RELATED PROTEIN-PROTEIN INTERACTIONS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023025307-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) | 2023-03-02 | — | — | WO | disclosed |
| CN-115485025-A | Compounds and methods for modulating splicing | 雷密克斯医疗公司 | 2022-12-16 | — | — | CN | disclosed |
| CN-114786771-A | Quinazoline derivatives as inhibitors of LPA receptor 2 | 奇斯药制品公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-114380841-A | Tricyclic or dihydroquinazoline compounds as AKT inhibitors | 南京正大天晴制药有限公司 | 2022-04-22 | — | — | CN | disclosed |
| US-20120046269-A1 | Novel Amino Azaheterocyclic Carboxamides | MERCK PATENT GMBH (DE) | 2012-02-23 | — | — | US | disclosed |
| CN-102317269-A | Novel amino aza heterocyclic carboxamides | MERCK PATENT GMBH | 2012-01-11 | — | — | CN | disclosed |
| CN-101824043-A | The composition that can be used as kinases inhibitor | VERTEX PHARMA | 2010-09-08 | — | — | CN | disclosed |
| CN-1894258-B | Compositions useful as protein kinase inhibitors | VERTEX PHARMA CO LTD | 2010-06-16 | — | — | CN | disclosed |
| US-20080275022-A1 | Substituted Quinazolones as Anti-Cancer Agents | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | US | disclosed |
| CN-1894258-A | Compositions useful as protein kinase inhibitors | VERTEX PHARMA (US) | 2007-01-10 | — | — | CN | disclosed |
| EP-0094080-B1 | PYRIDO(2,1-B)QUINAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1987-09-09 | — | — | EP | disclosed |
| US-4551460-A | ANTICOAGULANTS, CARDIOVASCULAR DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1985-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275022-A1 | Substituted Quinazolones as Anti-Cancer Agents | BRAF, NRAS, RAF1 | ALDH1A1 619/4885NR4A1 3632/4885NR4A2 3812/4885 |
| US-20120046269-A1 | Novel Amino Azaheterocyclic Carboxamides | AZI2, MKI67, MYC | ALDH1A1 1168/4885NR4A1 669/4885NR4A2 388/4885 |
| US-20130018033-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | ALDH1A1 1048/4885NR4A1 2235/4885NR4A2 3113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.